These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 20127948)

  • 1. Vascular endothelial growth factor receptor-1 in human cancer: concise review and rationale for development of IMC-18F1 (Human antibody targeting vascular endothelial growth factor receptor-1).
    Schwartz JD; Rowinsky EK; Youssoufian H; Pytowski B; Wu Y
    Cancer; 2010 Feb; 116(4 Suppl):1027-32. PubMed ID: 20127948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
    Wu Y; Zhong Z; Huber J; Bassi R; Finnerty B; Corcoran E; Li H; Navarro E; Balderes P; Jimenez X; Koo H; Mangalampalli VR; Ludwig DL; Tonra JR; Hicklin DJ
    Clin Cancer Res; 2006 Nov; 12(21):6573-84. PubMed ID: 17085673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth.
    Laakkonen P; Waltari M; Holopainen T; Takahashi T; Pytowski B; Steiner P; Hicklin D; Persaud K; Tonra JR; Witte L; Alitalo K
    Cancer Res; 2007 Jan; 67(2):593-9. PubMed ID: 17234768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fetal stromal-dependent paracrine and intracrine vascular endothelial growth factor-a/vascular endothelial growth factor receptor-1 signaling promotes proliferation and motility of human primary myeloma cells.
    Vincent L; Jin DK; Karajannis MA; Shido K; Hooper AT; Rashbaum WK; Pytowski B; Wu Y; Hicklin DJ; Zhu Z; Bohlen P; Niesvizky R; Rafii S
    Cancer Res; 2005 Apr; 65(8):3185-92. PubMed ID: 15833849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis.
    Shibuya M
    Angiogenesis; 2006; 9(4):225-30; discussion 231. PubMed ID: 17109193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of vascular endothelial growth factor receptors on tumor cells in head and neck squamous cell carcinoma.
    Lalla RV; Boisoneau DS; Spiro JD; Kreutzer DL
    Arch Otolaryngol Head Neck Surg; 2003 Aug; 129(8):882-8. PubMed ID: 12925349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms.
    Huh JI; Calvo A; Stafford J; Cheung M; Kumar R; Philp D; Kleinman HK; Green JE
    Oncogene; 2005 Jan; 24(5):790-800. PubMed ID: 15592523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2.
    Roberts N; Kloos B; Cassella M; Podgrabinska S; Persaud K; Wu Y; Pytowski B; Skobe M
    Cancer Res; 2006 Mar; 66(5):2650-7. PubMed ID: 16510584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines.
    Wey JS; Fan F; Gray MJ; Bauer TW; McCarty MF; Somcio R; Liu W; Evans DB; Wu Y; Hicklin DJ; Ellis LM
    Cancer; 2005 Jul; 104(2):427-38. PubMed ID: 15952180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
    Bruns CJ; Liu W; Davis DW; Shaheen RM; McConkey DJ; Wilson MR; Bucana CD; Hicklin DJ; Ellis LM
    Cancer; 2000 Aug; 89(3):488-99. PubMed ID: 10931447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
    Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
    Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma.
    Posey JA; Ng TC; Yang B; Khazaeli MB; Carpenter MD; Fox F; Needle M; Waksal H; LoBuglio AF
    Clin Cancer Res; 2003 Apr; 9(4):1323-32. PubMed ID: 12684400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular endothelial growth factor receptor-1 regulates postnatal angiogenesis through inhibition of the excessive activation of Akt.
    Nishi J; Minamino T; Miyauchi H; Nojima A; Tateno K; Okada S; Orimo M; Moriya J; Fong GH; Sunagawa K; Shibuya M; Komuro I
    Circ Res; 2008 Aug; 103(3):261-8. PubMed ID: 18583712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells.
    List AF; Glinsmann-Gibson B; Stadheim C; Meuillet EJ; Bellamy W; Powis G
    Exp Hematol; 2004 Jun; 32(6):526-35. PubMed ID: 15183893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.
    Lamszus K; Brockmann MA; Eckerich C; Bohlen P; May C; Mangold U; Fillbrandt R; Westphal M
    Clin Cancer Res; 2005 Jul; 11(13):4934-40. PubMed ID: 16000592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An autocrine loop directed by the vascular endothelial growth factor promotes invasiveness of human melanoma cells.
    Lacal PM; Ruffini F; Pagani E; D'Atri S
    Int J Oncol; 2005 Dec; 27(6):1625-32. PubMed ID: 16273219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of multiple vascular endothelial growth factor receptors (VEGFR) blocks lymph node metastases but inhibition of VEGFR-2 is sufficient to sensitize tumor cells to platinum-based chemotherapeutics.
    Sini P; Samarzija I; Baffert F; Littlewood-Evans A; Schnell C; Theuer A; Christian S; Boos A; Hess-Stumpp H; Foekens JA; Setyono-Han B; Wood J; Hynes NE
    Cancer Res; 2008 Mar; 68(5):1581-92. PubMed ID: 18316624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts.
    Davis DW; Inoue K; Dinney CP; Hicklin DJ; Abbruzzese JL; McConkey DJ
    Cancer Res; 2004 Jul; 64(13):4601-10. PubMed ID: 15231672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells.
    Yang AD; Camp ER; Fan F; Shen L; Gray MJ; Liu W; Somcio R; Bauer TW; Wu Y; Hicklin DJ; Ellis LM
    Cancer Res; 2006 Jan; 66(1):46-51. PubMed ID: 16397214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.